Compare Signpost Corp. (Tokyo) with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 4.79%
- The company has been able to generate a Return on Equity (avg) of 4.79% signifying low profitability per unit of shareholders funds
2
The company has declared negative results in Feb'2025 after 5 consecutive positive quarters
3
With ROE of 14.34%, it has a attractive valuation with a 2.44 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 3,609 Million (Micro Cap)
17.00
NA
0.00%
-0.75
5.18%
2.00
Revenue and Profits:
Net Sales:
797 Million
(Quarterly Results - Nov 2025)
Net Profit:
25 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.51%
0%
-2.51%
6 Months
-12.82%
0%
-12.82%
1 Year
-32.17%
0%
-32.17%
2 Years
-47.18%
0%
-47.18%
3 Years
-54.89%
0%
-54.89%
4 Years
-70.27%
0%
-70.27%
5 Years
-73.33%
0%
-73.33%
Signpost Corp. (Tokyo) for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.34%
EBIT Growth (5y)
25.66%
EBIT to Interest (avg)
-64.17
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.67
Sales to Capital Employed (avg)
1.41
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.37%
ROE (avg)
4.79%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
2.44
EV to EBIT
15.97
EV to EBITDA
15.96
EV to Capital Employed
5.36
EV to Sales
1.06
PEG Ratio
0.23
Dividend Yield
NA
ROCE (Latest)
33.54%
ROE (Latest)
14.34%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Nov'25 - QoQ
Nov'25
Aug'25
Change(%)
Net Sales
797.10
751.00
6.14%
Operating Profit (PBDIT) excl Other Income
27.30
-0.80
3,512.50%
Interest
1.30
1.70
-23.53%
Exceptional Items
-0.40
0.00
Consolidate Net Profit
25.00
-2.20
1,236.36%
Operating Profit Margin (Excl OI)
34.00%
-1.20%
3.52%
USD in Million.
Net Sales
QoQ Growth in quarter ended Nov 2025 is 6.14% vs 6.87% in Aug 2025
Consolidated Net Profit
QoQ Growth in quarter ended Nov 2025 is 1,236.36% vs 91.02% in Aug 2025
Annual Results Snapshot (Consolidated) - Feb'25
Feb'25
Feb'24
Change(%)
Net Sales
3,023.50
2,929.70
3.20%
Operating Profit (PBDIT) excl Other Income
200.20
101.80
96.66%
Interest
2.70
6.50
-58.46%
Exceptional Items
-1.30
-20.00
93.50%
Consolidate Net Profit
257.20
128.80
99.69%
Operating Profit Margin (Excl OI)
66.20%
34.70%
3.15%
USD in Million.
Net Sales
YoY Growth in year ended Feb 2025 is 3.20% vs 13.81% in Feb 2024
Consolidated Net Profit
YoY Growth in year ended Feb 2025 is 99.69% vs 197.13% in Feb 2024
About Signpost Corp. (Tokyo) 
Signpost Corp. (Tokyo)
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






